Eric Topol is Executive Vice President of Scripps Research, professor of molecular medicine, and the founder/director of the Scripps Research Translational Institute in La Jolla, CA. A pioneering interventional cardiologist turned digital-medicine leader, he’s one of the most cited physician-scientists in the world. His institute’s mission: use genomic, digital, and AI tools to individualize medicine. Topol has written bestselling books that translate frontier science for clinicians and the public.
Notable recent work
In 2025, Topol released Super Agers: An Evidence-Based Approach to Longevity, a data-driven counterweight to anti-aging hype. The book distills decades of research on how behaviors, sensors, biomarkers and — increasingly — AI can extend health span, not just lifespan. It drew mainstream coverage (from The Guardian and The Wall Street Journal) and public events at Scripps, positioning Topol at the center of a more rigorous longevity conversation. The through-line is evidence over fads: personalized prevention powered by objective measures, genetics, and machine-learning signals.
Topol’s institute continues to run and advise studies on AI for diagnostics, digital trials, and large-scale real-world data efforts. Scripps’ recent communications and features highlight how AI is reshaping fields from radiology to cardiology, focusing on rigorous validation and equitable deployment themes Topol has emphasized for years. His stance: AI must be clinically meaningful, bias-aware, and embedded into workflow, not sold as shiny objects.
Why he matters to your readers.
For executives and entrepreneurs, Topol models how to balance hype vs. proof. He champions randomized evaluations of digital tools, open science, and better data standards not because they’re academic ideals, but because they’re prerequisites for trust and scale. His out-front advocacy helped catalyze funding and NIH support for translational infrastructure, and he frequently briefs policymakers and health-system leaders on what “responsible AI” should look like at the bedside.
The business & policy angle
As payers begin tying reimbursement to quality metrics that AI might influence, Topol’s pragmatism is a valuable North Star: measure the outcomes, audit the biases, and publish the methods. For your profile, connect his longevity book to the institute’s pipeline — prevention isn’t just lifestyle advice; it’s also continuous measurement, algorithmic risk prediction, and earlier detection of disease. That’s fertile ground for entrepreneurs, life-science partnerships, and providers building population-health programs that actually bend cost curves.
Why now.
With Super Agers fresh on shelves, continued Scripps programming, and ongoing media discussion of AI and aging, Topol gives you a timely hook with wide public interest — and the credibility of a clinician-scientist who has shaped this field for over a decade.
